Bromocriptine vaginal

All available dopamine agonists are active as oral preparations, and all are eliminated by metabolism. They can also be absorbed systemically after vaginal insertion of tablets. Cabergoline, with a half-life of approximately 65 hours, has the longest duration of action. Quinagolide has a half-life of about 20 hours, whereas the half-life of bromocriptine is about 7 hours. After vaginal administration, serum levels peak more slowly. 

Bromocriptine Activates dopamine D2 receptors Suppresses pituitary secretion of prolactin dopaminergic effects on CNS motor control and behavior Treatment of hyperprolactinemia and Parkinson s disease (see Chapter 28) Administered orally or vaginally Toxicity Gastrointestinal disturbances, orthostatic hypotension, headache, psychiatric disturbances, vasospasm and pulmonary infiltrates in high doses... 

A vaginal suppository based on bromocriptine was employed for the therapy of hyperprolactinemia [32]. The rationale of the local vaginal delivery of bromocriptine lies in the noteworthy side effects consequent to oral therapy gastrointestinal disorders, extensive hepatic degradation, and hypotension. The pessary based on bromocriptine proved to be effective in lowering serum prolactin to normal levels after 20 days of local therapy the treatment was well tolerated by the majority of the patients and a minimal vaginal irritation was observed. 

Darwish, A.M., et al. 2005. Evaluation of novel vaginal bromocriptine mesylate formulation A pilot study. Fertil Steril 83 1055. 

Bromocriptine Therapy of hyperprolactinemia Oral tablet and vaginal suppository Proved to be effective and safe, without the adverse effects of oral administration vaginal suppository obtained higher reduction in serum prolactin 330... 

Acarturk, F., and Altug, N. (2001), In-vitro and in-vivo evaluation of a matrix-controlled bromocriptine mesilate-releasing vaginal ring, / Pharm, Pharmacol., 53,1721-1726. 

Jasonni VM, Raffelli R, de March A, Frank G, Flamigni C. Vaginal bromocriptine in hyperprolactinemic patients and puerperal women. Acta Obstet Gynecol Scand 1991 70(6) 493-5. 

The most common adverse effects associated with bromocriptine therapy inclnde central nervous system symptoms such as headache, lightheadedness, dizziness, nervousness, and fatigue. Gastrointestinal effects such as nausea, abdominal pain, and diarrhea are also common. Bromocriptine should be administered with food to decrease the incidence of adverse gastrointestinal effects. Although most of these adverse effects diminish with continued treatmenfi about 12% of patients will not tolerate the adverse effects associated with bromocriptine therapy. Vaginal preparations of bromocriptine have been studied in an effort to decrease the incidence of adverse effects associated with oral dosage forms. ... 

Carranza-Lira S, Gonzalez-Sanchez JL, Martinez-Chequer JC. Vaginal bromocriptine administration in patients with hyperprolactinemia. Int J Gynaecol Obstet 1999 65 77-78. 

---